Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24221255 | 1.00 | KISS1R (0.38) | KISS1REPHX1CPB2MEN1KMT2A | |
| SCHEMBL19545990 | 0.86 | KDM4E (0.34) | EPHX1MEN1KMT2ACTSKSIRT6 | |
| SCHEMBL22951230 | 0.84 | KISS1R (0.37) | KISS1REPHX1CPB2MEN1KMT2A | |
| SCHEMBL23707734 | 0.84 | KISS1R (0.37) | KISS1REPHX1CPB2MEN1KMT2A | |
| SCHEMBL20235709 | 0.83 | KDM4E (0.47) | EPHX1MEN1KMT2ASIRT6SIRT1 | |
| SCHEMBL24157441 | 0.82 | KISS1R (0.47) | KISS1REPHX1CPB2SIRT6SIRT1 | |
| SCHEMBL24410436 | 0.82 | CPB2 (0.40) | KISS1RCPB2MEN1KMT2A | |
| SCHEMBL21297374 | 0.81 | KISS1R (0.39) | KISS1REPHX1CPB2 | |
| SCHEMBL14252281 | 0.81 | KISS1R (0.35) | KISS1REPHX1CPB2MEN1KMT2A | |
| SCHEMBL16692066 | 0.81 | KISS1R (0.39) | KISS1REPHX1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | NOSOPHARM (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | VIP, IAPP, NGLY1 | KISS1R 381/4885EPHX1 4301/4885CPB2 236/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | KISS1R 381/4885EPHX1 4301/4885CPB2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.